FOLLOW-ON ARTICLE: The Drug’s Status Changed. The Payment Answer Did Not.

HHS OIG reported that Medicare Part D sponsors made $587.7 million in ineligible payments during 2021–2023 for five drugs associated with obsolete prescription-only labeling. Its summary identifies obsolete FDA data in a CMS reference file and the absence of a rejection timeframe. This was a payment-information failure; the report does not establish an AI failure.

Imagine an employer health plan using an AI assistant to answer a prescription-benefit question. Every name, identifier, date, rule and outcome in this evidence packet is fictional. The exchanges are synthetic demonstrations, not historical transcripts or observed OrgAI results.

Fictional evidence packet

• H1 — Fictional plan rule: The employer health plan excludes over-the-counter products from its prescription benefit. An authorized status notice overrides the older formulary for affected claims.
• H2 — Old entry: Product Lumen-A, package LA-20, is listed as prescription-only in the January 2026 formulary.
• H3 — Current notice: The plan’s authorized pharmacy office changes LA-20 to over-the-counter status effective September 1, 2026. The notice explicitly supersedes H2 for claims on or after that date.
• H4 — Questioned claim: LA-20, dispensed September 15, 2026. No applicable exception is recorded.

Discontinuous response — synthetic

Prompt: Is the September 15 LA-20 claim covered by our prescription benefit?

Response: Yes. LA-20 appears as prescription-only in the formulary, so this claim is covered.

Follow-up prompt: Does the September 1 status notice change that answer?

Response: The notice describes a change, but the formulary still lists the product. I would continue treating the claim as covered.

Future-use prompt: If this claim is reviewed again tomorrow, which status should govern?

Response: Use the January formulary again; it lists LA-20 as prescription-only.

Graph callout: The old entry remains in charge after its authority has ended.

GovKM continuity analysis and proposed solution

The missing relationship is specific: H3 supersedes H2 for this product and date. Both documents can remain available, but they cannot carry equal authority for the September 15 question. Finding the old formulary is insufficient if the answer drops the later notice’s effective date and scope.

GovKM’s continuity analysis asks whether the product, governing notice and claim date remain connected. The intended improvement is an answer that uses the current authorized status while preserving the earlier entry as history. It does not require erasing what the plan previously said.

Continuous response — synthetic intended outcome

Same prompt: Is the September 15 LA-20 claim covered by our prescription benefit?

Response: No, under this fictional plan’s stated rules. H3 changes LA-20 to over-the-counter status from September 1 and supersedes the older entry. The September 15 claim falls after that date, and H4 records no exception.

Same follow-up: Does the September 1 status notice change that answer?

Response: Yes. H3 changes which entry governs this claim. H2 remains evidence of the earlier status, but it does not authorize prescription-benefit coverage on September 15. This answer concerns plan payment, not medical suitability or treatment.

Same future-use prompt: If this claim is reviewed again tomorrow, which status should govern?

Response: For the same September 15 claim, H3 still governs: the September 1 change makes it ineligible under H1. Check for any later authorized correction before reuse; none is present in this packet.

Graph callout: The same product and claim date now lead to the governing status.

Both diagrams use the same six objects. Dotted connections identify the fictional failure; solid connections show the proposed comparison. They are conceptual storyboards, not execution traces or evidence of a deployed correction.

OrgAI and organizational continuity

OrgAI is GovKM’s specified continuity architecture, designed to preserve evidence, authority, context, decisions and records over time. Human judgment remains essential.

The demonstrated answer follows this fictional packet. It is not a product-performance guarantee.

Sources

• Existing GovKM analysis.
• HHS OIG, Medicare Part D obsolete-label audit summary.
• OrgAI’s public description.